Lucía Carril-Ajuria
A5056466515- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- MicroRNA in disease regulation
- Cancer Treatment and Pharmacology
Institut Gustave Roussy
2020-2024
Université Paris-Saclay
2022-2024
Centre Hospitalier Universitaire Brugmann
2023-2024
Centre Hospitalier Universitaire de Saint-Pierre
2023-2024
Centre National de la Recherche Scientifique
2024
Inserm
2024
Research Institute Hospital 12 de Octubre
2018-2022
Hospital Universitario 12 De Octubre
2018-2022
Hospital Universitario HM Madrid
2022
Comunidad de Madrid
2020-2022
Background The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal carcinoma (m-ccRCC) a ‘real-world setting’. We conducted translational-research program to determine whether specific circulating immune-cell populations and/or soluble factors at baseline were predictive clinical outcomes m-ccRCC treated within the study. Methods Absolute numbers 106 prospectively analyzed single institution trial available...
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets patients and is now standard care several solid tumor types. However, immunotherapy activity beyond conventional immune checkpoint inhibition plateauing, biomarkers are overall lacking to guide treatment selection. Most studies have focused on T cell engagement response, but there a growing evidence that B cells may be key players establishment an organized notably through tertiary...
Abstract Background MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive subgroup of harboring high expression c-MET. While TRCC response rates to VEGF receptor tyrosine kinase inhibitors (TKIs) immune checkpoint are limited, efficacy cabozantinib (a VEGFR, MET, AXL inhibitor) in this unclear. Methods We performed multicenter, retrospective, international cohort study patients with treated cabozantinib. The main objectives were estimate rate according RECIST 1.1...
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients Methods We performed a retrospective cohort study collecting clinicopathological, treatment, outcome data for aUC ICIs from 2013 to 2020 across 24 institutions. compared objective response rate (ORR), overall survival (OS), progression‐free (PFS) UC (UTUC, LTUC). Uni‐...
Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy prognostic factors. We assessed factors associated with better outcomes. Patients Methods. This ambispective multicenter study included 45 mRCC patients rechallenged nivolumab ± ipilimumab between 2014 2020. Primary...
Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of CARMENA and SURTIME trials, cytoreductive is no longer standard care patients requiring upfront systemic treatment it should be avoided most poor-risk patients. Nevertheless, still considered responding therapy good-risk not treatment. This case series phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may able induce rapid significant...
4552 Background: The NIVOREN GETUG-AFU 26 study launched a translational research program to quantify baseline circulating soluble factors levels and correlate them with outcomes nivolumab in mRCC pts. We previously identified on training set (n = 80, 40 responders/40 progressors) several significantly associated worse overall survival (OS), progression-free (PFS) response (IL-8 VEGF), or OS only (IL-6, IL-7) (Carril-Ajuria et al. ASCO GU. 2022). Our aim was confirm these findings using an...
To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients advanced urothelial carcinoma (aUC) who have vs not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease.We performed a retrospective cohort study collecting clinicopathological, treatment and data for aUC receiving ICIs across 25 institutions. We compared (observed response rate [ORR], progression-free survival [PFS], overall [OS]) between...